Abstract Pleomorphic xanthoastrocytoma (PXA) is a World Health Organization (WHO) Grade II glioma occurring primarily in children and young adults. Most PXAs harbor the known activating mutation BRAF V600E. We report a case of locally recurrent PXA with anaplastic features in a 10-yr-old female. The PXA was negative by immunohistochemical (IHC) staining for BRAF V600E mutation. Whole-exome and transcriptome sequencing of the tumor confirmed the absence of BRAF V600E, but identified copy-number alterations (including loss of the tumor suppressor CDKN2A) and a novel TMEM106B-BRAF fusion. Based on similar BRAF fusion proteins, this novel fusion is predicted to result in activation of BRAF signaling. Demonstration of positive IHC for phospho-ERK1/2 and phospho-MEK1/2 supported this prediction, and implicated MEK inhibitors as a potential therapeutic strategy.
reagent V5+UTRs and sequenced on the Illumina HiSeq2500. An average coverage of 214-and 181-fold was obtained in the normal and tumor samples, respectively. Potential variants were filtered by known pathogenicity (ClinVar, Human Gene Mutation Database [HGMD] , Online Mendelian Inheritance in Man [OMIM] , Catalogue of Somatic Mutations in Cancer [COSMIC] ) and frequency in the general population (The 1000 Genomes Project, Exome Variant Server, and our internal database). Copy-number changes were defined using EXCAVATOR software (Magi et al. 2013) . Transcriptome sequencing was performed on RNA isolated from tumor. Transcriptome alignment was performed using the Tuxedo suite software package (Trapnell et al. 2012) . One hundred and forty-eight million uniquely mapped reads were obtained. Translocations were detected using the FusionMap software. In view of BRAF V600E negativity, tumor was subjected to further IHC staining on formalin-fixed paraffin-embedded (FFPE) sections using standard procedures and the following antibodies: IgG control (sc-2027, Santa Cruz Biotechnology, Inc.), phospho-ERK1/2 (4370, Cell Signaling Technology), and phospho-MEK1/2 (2338, Cell Signaling Technology).
Genomic Analysis
A total of 124 somatic variants were identified and evaluated for pathogenicity and clinical significance. None were found to be clinically significant. Somatic copy-number changes identified included gain of Chromosome 7 (1-159,138,663), loss of Chromosome 13 (1-115,169,878), and copy-number neutral loss of heterozygosity of 9p (1-47,432,582) with copy-number loss of 9p21. 3 (20,902,560-23,776,437 , which includes the CDKN2A gene). Of note, transcriptome sequencing detected a novel TMEM106B-BRAF fusion on Chromosome 7, involving exons 1-3 of TMEM106B fused to exons 8-18 of BRAF ( Fig. 1A ; Table 1 ).
Clinical Interpretation
The primary treatment of PXA is surgical resection, and the outcome is generally favorable. Pathology is notable for anaplasia in ∼15% of PXAs, but there is no consensus regarding any advantage of adjuvant postsurgical therapy (Perkins et al. 2012) . BRAF V600E mutation is found in nearly 70% of PXAs (Dias-Santagata et al. 2011 ). Activation of BRAF by chromosomal rearrangement, such as the KIAA1549-BRAF fusion, which is common in pilocytic astrocytomas, is rare in PXA (Antonelli et al. 2015) . BRAF is a serine/threonine kinase downstream from RAS in the mitogen-activated protein kinase (MAPK) signaling pathway. Mutation in BRAF constitutively activates the RAS/RAF/MEK/ERK signaling pathway. The possibility of targeted therapy for BRAF V600E mutated PXA has now been realized, with the report of transient single-agent activity of the selective BRAF V600E inhibitor vemurafenib (Chamberlain 2013) . TMEM106B functions in dendrite morphogenesis and maintenance by regulating lysosomal trafficking and may be associated with frontotemporal dementia. The TMEM106B-BRAF fusion in our case results in replacement of the amino-terminal regulatory domain of BRAF with the amino-terminal region of TMEMB106B while leaving the kinase domain of BRAF intact (Fig. 1B) . Although not previously reported, this fusion is predicted to result in activation of BRAF signaling, based on the activity of similar BRAF fusion proteins. We used activation-state-specific immunohistochemical staining for phospho-ERK1/2 and phospho-MEK to demonstrate activation of the MEK-ERK pathway downstream from BRAF signaling (Fig. 1C) . Given reports showing that tumors harboring the KIAA1549-BRAF fusion are not sensitive to vemurafenib and lead to paradoxical MEK-ERK activation, we expect PXA harboring TMEM106B-BRAF fusion will not be sensitive to vemurafenib as well, but could be sensitive to MEK inhibitors or second-generation RAF inhibitors such as PLX8394 (Sievert et al. 2013; Karajannis et al. 2014; Zhang et al. 2015) .
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